+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Protective Effect of Triflusal against Acute Myocardial Infarction in Patients with Unstable Angina: Results of a Spanish Multicenter Trial

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          A multicenter, double-blind, placebo-controlled study was carried out to evaluate the effect of a new antiplatelet agent, triflusal (2-acetoxy-4-trifluoromethyl benzoic acid), in the prevention of nonfatal myocardial infarction and cardiac or vascular death (principal end-points) in patients with unstable angina. 281 patients were randomly assigned to triflusal (300 mg t.i.d.; n = 143) or placebo (n = 138). After 6 months of treatment, the incidence of nonfatal acute myocardial infarction was significantly lower in the triflusal than in the placebo group: 6 patients (4.2%) versus 17 (12.3%), p = 0.013. The low number of deaths (2/143 triflusal versus 0/138 placebo recipients) hampered statistical analysis of mortality rates. The need for revascularization was similar in the two groups: 24 patients (16.8%) in the triflusal group and 28 (20.3%) in the placebo group, p = 0.449. In conclusion, the results show that treatment with triflusal can reduce the incidence of myocardial infarction in patients with unstable angina.

          Related collections

          Author and article information

          S. Karger AG
          14 November 2008
          : 82
          : 6
          : 388-398
          aInstituto de Salud Carlos III; bHospital Provincial Gregorio Marañón; cCiudad Sanitaria La Paz, Madrid; dClínica Universitaria, Pamplona; eHospital Virgen de la Macarena, Sevilla; fHospital General, Valencia; s gCiudad Sanitaria Virgen da la Arrixaca, Murcia; hCiudad Sanitaria Carlos Haya, Malaga; iHospital Miguel Servet, Zaragoza; jCiudad Sanitaria La Fe, Valencia; kInstituto de Cardiología, Pabellón I, Ciudad Universitaria, Madrid, Spain
          175892 Cardiology 1993;82:388–398
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Catheterization and Interventional Cardiology


          Comment on this article